NEWS RELEASE - PRESSEMITTEILUNG

Acino announces change of CEO Aesch, December 18, 2013, 17.30 hrs - Peter Burema, CEO of the Acino Group, has decided to leave the company with immediate effect to pursue new opportunities outside Acino. On an interim basis, Dr. Håkan Björklund will assume the function of Group CEO in addition to his new role as Chairman of Acino Holding AG.

Peter Burema served as CEO of the Acino Group since March 2010. He was instrumental in broadening the company's geographic business reach and diversifying its customer base. Under his leadership, Acino successfully acquired Mepha's international business based in Aesch with its direct to consumer business in the Middle East, Africa, Latin America and Asia. The Board of Directors and the Members of Group Management thank Peter Burema for his contribution and personal commitment and wish him every success in his future activities.

About Acino


Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand "Acino Switzerland", Acino markets Swiss-quality medicines in up and coming economies, currently 80 countries in the Middle East, Africa, Latin America and Asia. The Acino Group, headquartered in Aesch BL, has 788 employees and generated revenues of EUR 143 million in the first half-year 2013.
On December 12, 2013, Pharma Strategy Partners GmbH, a wholly-owned subsidiary of Avista Capital Partners and Nordic Capital, successfully completed its public tender offer for Acino Holding AG. Pharma Strategy Partners GmbH intends to effect a full takeover of Acino, and will delist the Acino shares from the stock exchange.

Contact Calendar


Robert Schmid
Media & Investor Relations Phone +41 61 338 61 15 robert.schmid@acino-pharma.com
www.acino-pharma.com

6.3.2014 Annual Report 2013
6.3.2014 Media and analyst conferences
10.4.2014 General Meeting of Shareholders

Acino Holding AG

Dornacherstrasse 114

CH-4147 Aesch

Phone +41 61 338 60 00

Fax +41 61 338 60 80 www.acino-pharma.com

distributed by